论文信息 - Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma

Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma

This case series describes the kinetics of humoral deficiency in patients with relapsed refractory multiple myeloma treated with bispecific antibodies, the infectious complications, and response to COVID-19 immunization.

[1] P. Hari,et al. Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma , 2021, Blood advances.

[2] Junnian Zheng,et al. Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma , 2021, Blood advances.

[3] Chiung-Yu Huang,et al. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy , 2021, Blood advances.

[4] A. Krishnan,et al. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study , 2021, The Lancet.

[5] A. Chari,et al. Bispecifics, trispecifics, and other novel immune treatments in myeloma. , 2020, Hematology. American Society of Hematology. Education Program.

[6] S. Grupp,et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.